Zhang Bo, Fang Yanfen, Cao Ji, Zhang Chong, Ying Meidan, He Qiaojun, Yang Bo
Institute of Pharmacology and Toxicology, School of Pharmaceutical Sciences, Zhejiang University, Hangzhou, Zhejiang 310058, China.
J Cancer Res Clin Oncol. 2008 Mar;134(3):373-9. doi: 10.1007/s00432-007-0293-y. Epub 2007 Aug 7.
Staphylococcus Aureus Filtrate Preparation (SAFP) is a preparation of low-virulence strain of Staphylococcus aureus. In our study, we aimed to determine the anti-tumor activity of SAFP in vivo and explore the potential mechanism.
Our study evaluated the anti-tumor activity of SAFP in four cancer cell models in vivo and determined its up-regulatory effects on mice immune system in vivo.
It showed that 7.2 ng/10 g SAFP could inhibit the progression of murine hepatoma H22 and sarcoma S180, and the tumor inhibition rates achieved 48.1 and 35.7%, respectively. In human non-small cell lung cancer A549 and hepatoma BEL7402 xenograft athymic mice models, T/C of 7.2 ng/10 g SAFP group reached 41.0% in A549 model and 21.0% in BEL7402 model. Meanwhile, SAFP also significantly increased the proliferation of cultured mice splenocytes to 162.1%, and 7.2 ng/kg SAFP significantly (P < 0.001) raised the activity of NK cells, elevated the serum level of IL-2, TNF-alpha and IFN-gamma in mice.
SAFP exhibited high efficiency in inhibiting the growth of cancer cells in a dose-dependent manner, which possibly attributed to its regulatory effects of immune system.
金黄色葡萄球菌滤液制剂(SAFP)是一种低毒力金黄色葡萄球菌菌株的制剂。在我们的研究中,旨在确定SAFP在体内的抗肿瘤活性并探索其潜在机制。
我们的研究评估了SAFP在四种体内癌细胞模型中的抗肿瘤活性,并确定了其对小鼠免疫系统的上调作用。
结果显示,7.2 ng/10 g的SAFP可抑制小鼠肝癌H22和肉瘤S180的进展,肿瘤抑制率分别达到48.1%和35.7%。在人非小细胞肺癌A549和肝癌BEL7402异种移植裸鼠模型中,7.2 ng/10 g的SAFP组在A549模型中的T/C达到41.0%,在BEL7402模型中达到21.0%。同时,SAFP还显著将培养的小鼠脾细胞增殖提高到162.1%,7.2 ng/kg的SAFP显著(P < 0.001)提高了NK细胞的活性,提高了小鼠血清中IL-2、TNF-α和IFN-γ的水平。
SAFP在抑制癌细胞生长方面表现出高效性,且呈剂量依赖性,这可能归因于其对免疫系统的调节作用。